EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells

EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells

Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of a...

Full description

Bibliographic Details
Main Authors: Christopher J. Stairiker, Sophia Xiao Pfister, Eleanore Hendrickson, Wenjing Yang, Tao Xie, Catherine Lee, Haikuo Zhang, Christopher Dillon, Graham D. Thomas, Shahram Salek-Ardakani
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
EZH2
CD8
T cell
Bim
CD137 (4-1BB)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.770080/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.770080/full

Similar Items